Genprex Inc., a clinical-stage gene therapy company, recently announced positive preclinical results for its diabetes gene therapy, GPX-002. Presented at the American Society of Gene and Cell Therapy's 28th Annual Meeting, the study highlights the potential of GPX-002 in treating both Type 1 and Type 2 diabetes. The therapy utilizes intraductal infusion of recombinant adeno-associated virus to deliver Pdx1 and MafA genes, converting alpha cells into insulin-secreting beta-like cells. In mouse models, this approach successfully reversed diabetes without the need for immunosuppression. However, in non-human primate models, an anti-viral immune response was observed, which initially affected glucose tolerance improvements. Researchers found that administering a multi-agent immunosuppression regimen could largely prevent this immune response, sustaining therapeutic effects. Ongoing studies aim to gather further data on the viral efficacy of GPX-002 after six months of immunosuppression in non-human primate models.